Published in Gastroenterol Clin Biol on February 23, 2010
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect (2012) 7.97
Genome sequence of the plant pathogen Ralstonia solanacearum. Nature (2002) 6.23
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
The complete genome sequence of Lactobacillus bulgaricus reveals extensive and ongoing reductive evolution. Proc Natl Acad Sci U S A (2006) 3.11
Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst (1995) 3.00
The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics. Eur J Clin Microbiol Infect Dis (2013) 2.54
MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol (2001) 2.33
Sequence and analysis of chromosome 3 of the plant Arabidopsis thaliana. Nature (2000) 2.17
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol (2007) 2.15
Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol (2006) 2.14
Three-dimensional structure of extended chromatin fibers as revealed by tapping-mode scanning force microscopy. Proc Natl Acad Sci U S A (1994) 2.12
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol (2008) 2.10
Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol (1998) 2.06
Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol (2009) 2.06
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol (2002) 2.03
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol (2009) 1.92
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol (2012) 1.82
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS (1999) 1.75
TUNEL apoptotic cell detection in tissue sections: critical evaluation and improvement. J Histochem Cytochem (1998) 1.73
What happens to nucleosomes during transcription? J Biol Chem (1992) 1.68
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol (2013) 1.65
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol (2002) 1.61
In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem (1996) 1.60
Is it clinically possible to distinguish nonhemorrhagic infarct from hemorrhagic stroke? Stroke (1995) 1.60
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol (2010) 1.58
Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing. Eur J Clin Microbiol Infect Dis (2009) 1.55
The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone (2000) 1.55
Predictive factors of the response to chemoradiotherapy in esophageal cancer. Gastroenterol Clin Biol (2008) 1.44
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol (2008) 1.44
Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol (1997) 1.43
Influence of intraocular lens material on the development of acute endophthalmitis after cataract surgery? Eye (Lond) (2006) 1.43
Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. J Invest Dermatol (2000) 1.40
[Rhinophyma and skin carcinoma: a case report and literature review]. Ann Chir Plast Esthet (2011) 1.39
Chondroitin-4-sulfate impairs in vitro and in vivo cytoadherence of Plasmodium falciparum infected erythrocytes. Mol Med (1997) 1.39
Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther (2006) 1.38
Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient. Ann Oncol (2009) 1.38
High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol (1998) 1.37
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol (1992) 1.37
Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol (2011) 1.35
Epidermal differentiation does not involve the pro-apoptotic executioner caspases, but is associated with caspase-14 induction and processing. Cell Death Differ (2000) 1.32
Analysis of the lacZ sequences from two Streptococcus thermophilus strains: comparison with the Escherichia coli and Lactobacillus bulgaricus beta-galactosidase sequences. J Gen Microbiol (1991) 1.29
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol (2011) 1.29
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol (2001) 1.26
Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer (2013) 1.26
Isolation and characterization of brain microvascular endothelial cells from Saimiri monkeys. An in vitro model for sequestration of Plasmodium falciparum-infected erythrocytes. J Immunol Methods (1995) 1.26
Primary non-Hodgkin's lymphomas of the liver with nodular and diffuse infiltration patterns have different prognoses. Ann Oncol (2001) 1.22
Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol (2008) 1.22
Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract (2012) 1.21
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol (2013) 1.20
Culturomics identified 11 new bacterial species from a single anorexia nervosa stool sample. Eur J Clin Microbiol Infect Dis (2013) 1.19
Clinical variants of the preprotuberant stage of dermatofibrosarcoma protuberans. Br J Dermatol (2005) 1.19
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol (1997) 1.18
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol (2008) 1.18
High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol (2008) 1.17
Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. Virology (2012) 1.16
Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal (2009) 1.16
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol (1999) 1.14
Increased risk of unintentional dural puncture in night-time obstetric epidural anesthesia. Can J Anaesth (1999) 1.14
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol (2012) 1.11
Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol (2007) 1.11
Conjugative mobilization as an alternative vector delivery system for lactic streptococci. Appl Environ Microbiol (1987) 1.10
Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol (2009) 1.08
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology (2009) 1.08
The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia (1995) 1.07
Terminal differentiation of human epidermal keratinocytes involves mitochondria- and caspase-dependent cell death pathway. Cell Death Differ (2003) 1.07
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer (2010) 1.05
Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene (2012) 1.05
Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol (2007) 1.05
Electrochemotherapy: a new treatment of solid tumors. J Exp Clin Cancer Res (2003) 1.04
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Ann Oncol (2011) 1.04
Conditional suicide system of Escherichia coli released into soil that uses the Bacillus subtilis sacB gene. Appl Environ Microbiol (1993) 1.03
The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of alpha-fetoprotein or beta-human chorionic gonadotrophin: report of two cases. Ann Oncol (2002) 1.01
Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res (2000) 1.00
Rickettsia felis, from culture to genome sequencing. Ann N Y Acad Sci (2005) 0.99
Abnormal systolic intraventricular flow velocities after valve replacement for aortic stenosis. Mechanisms, predictive factors, and prognostic significance. Circulation (1996) 0.99
Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol (2005) 0.99
[Clinical and etiological aspects of uveitis: a retrospective study of 121 patients referred to a tertiary centre of ophthalmology]. Rev Med Interne (2010) 0.98
Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol (2011) 0.97
Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol (2007) 0.97
[Guidelines for the diagnosis and treatment of Merkel cell carcinoma]. Ann Dermatol Venereol (2011) 0.97
Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol (2009) 0.97
A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood (1998) 0.97
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol (1999) 0.97
Development of a French inpatient satisfaction questionnaire. Int J Qual Health Care (2001) 0.96
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol (2008) 0.96
Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma. Radiother Oncol (1999) 0.95
Gene expression profiling in blood cells of endurance horses completing competition or disqualified due to metabolic disorder. Equine Vet J Suppl (2006) 0.95
[Metastasis on previous hip arthroplasty: three cases]. Rev Chir Orthop Reparatrice Appar Mot (2005) 0.94
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. J Clin Oncol (1999) 0.94
Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer (2007) 0.94